Novartis/Orion Comtan Enters COMT Field Without Liver Warnings
Executive Summary
Novartis will launch Comtan into the catechol-O-methyltransferase inhibitor class without warnings concerning hepatic toxicity.
You may also be interested in...
Novartis Alzheimer's Drug Exelon Captures 25% Of New Rxs In U.S.
Novartis is finding room for new Rx growth in the Alzheimer's treatment category, where Exelon has nearly doubled its share of new Rxs in the past two months.
Novartis Alzheimer's Drug Exelon Captures 25% Of New Rxs In U.S.
Novartis is finding room for new Rx growth in the Alzheimer's treatment category, where Exelon has nearly doubled its share of new Rxs in the past two months.
Roche Tasmar Relabeling Adds Patient Consent Form Citing Liver Toxicity
The relabeling of Roche's Parkinson's therapy Tasmar (tolcapone) to reflect reports of severe liver toxicity includes a consent form requiring patients to acknowledge that they are risking fatal side effects by taking the drug.